In contrast, previous studies showed that treatment with roxadustat markedly improved hypertension and organ injury in an angiotensin II model of hypertension, possibly through stabilization of HIF1α and subsequent targeting of endothelial nitric oxide synthase (eNOS), AGTR1, AGTR2, and oxidative stress [56]. This evidence concerns the gene HIF1A and hypertensive disorder.